Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Enzinger

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
European Radiology|November 7, 2019
Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methodsA de Sitter, M Visser, I Brouwer, et al.
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Nature Medicine|January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trialJun Tian, Jonathan H Chen, Sherry X Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Cancer Research|July 4, 2012
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesisAustin M Dulak, Steven E Schumacher, Jasper van Lieshout, et al.
European Journal of Neurology|January 26, 2008
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI studyC Wegner, M Filippi, T Korteweg, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
European Radiology|November 7, 2019
Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methodsA de Sitter, M Visser, I Brouwer, et al.
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Nature Medicine|January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trialJun Tian, Jonathan H Chen, Sherry X Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Cancer Research|July 4, 2012
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesisAustin M Dulak, Steven E Schumacher, Jasper van Lieshout, et al.
European Journal of Neurology|January 26, 2008
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI studyC Wegner, M Filippi, T Korteweg, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Pageof 20